CSPAN2 Capital News Today December 23, 2011
focusing on some of the incentives that create the inefficiencies. >> yes, sir. right here. >> so i would like to talk -- or ask about your r&d and particularly a bunch of things are happening. one, with both genomic samp ergonomics, when you do clinical trials, you can now look at different populations, not just race or age or sex, genotypes and so forth good in many cases you're likely to discover the certain track is very good for a subset, useless for another subset and toxic for it. it's great for you to discover that. it means in theory you can target the drugs to a smaller pop...
Source: archive.org